Global Prostate Health Market - 2023-2030

Global Prostate Health Market - 2023-2030

Global Prostate Health Market reached US$ XX billion in 2022 and is expected to reach US$ XX million by 2030 growing at a CAGR of XX% during the forecast period 2023-2030.

The three primary conditions can affect the prostate namely benign prostatic hyperplasia (BPH) which is an expansion of the prostate gland brought on by aging, prostatitis, an infection or inflammation of the prostate, and prostate cancer which is the development of malignant cells within the prostate that have the potential to spread outside the gland and impact other body organs.

The prostate consists of connective tissues and glandular tissues that add fluid to the semen, and its muscles help push semen through the urethra. Acute prostatitis is caused by an infection, usually by bacteria, and results in the sudden onset of painful urination, a small stream, and often fever and chills.

Market Dynamics

Increasing drug approvals

The increasing drug approvals act as a significant driver for market growth. The prostate is responsible for producing seminal fluid that nourishes and transports sperm. It is vulnerable to three main conditions that is prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer.

For instance, in March 2023, the Chinese National Medical Products Administration (NMPA) approved the oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Additionally, in August 2023, the U.S. FDA approved AKEEGA (Niraparib and Abiraterone Acetate). It is the first and only dual action tablet for the treatment of patients with BRCA-positive metastatic castration-resistant prostate cancer.

Also, in March 2022, Novartis, a Swiss-American multinational pharmaceutical corporation received FDA approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the therapy of adult individuals suffering from a specific kind of progressive cancer named prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer

Furthermore, significant growth drivers such as the rising prevalence of prostate cancers, and increasing clinical trials for treatment drugs are expected to drive the market in the forecast period.

Stringent regulatory policies

The presence of stringent regulatory authority bodies approving the usage and commercialization of drugs or biologics employed in treating the prostate health market is hampering global market growth. For instance, the European Medicines Agency (EMA), an agency of the European Union in command of the evaluation and surveillance of pharmaceutical developments, and the U.S Food and Drug Administration (USFDA), a nationwide agency of the Department of Health and Human Services are prominent regulatory authoritative bodies among others.

Segment Analysis

The global prostate health market is segmented based on indication, treatment, end users, and region.

The radiation therapy segment accounted for approximately 41.8% of the market share

The radiation therapy segment is expected to hold the largest market share over the period forecast. Radiation therapy uses high-energy rays or particles to kill cancer cells. It is used depending on the stage of the prostate cancer and other factors. A total of 185 clinical trials were conducted for prostate cancer.

For instance, according to Clinicaltrials.gov, on April 4, 2023, the Proton Collaborative Group conducted a clinical trial on hypo-fractionated radiation therapy with or without androgen suppression for intermediate risk prostate cancer. It is currently in phase 3 trial and the expected study completion date is December 2025.

Additionally, on April 28, 2021, Lund University Hospital conducted a clinical trial on personalized radiotherapy for biochemical recurrence of prostate cancer after prostatectomy. It is currently in phase 3 trial. Hence, due to the above factors, the segment is expected to hold the largest market share.

Geographical Analysis

North America is expected to hold a significant position in the global prostate health market share

The global prostate health market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

North America has maintained a significant market proportion due to factors such as the rising prevalence of prostate cancer, drug approvals, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.

For instance, the American Cancer Society estimates for prostate cancer in the United States for 2023 are around 288,300 new cases of prostate cancer and about 34,700 deaths from prostate cancer

Additionally, in November 2023, Astellas Pharma Inc. and Pfizer Inc. received approval from the U.S. FDA of a supplemental New Drug Application for XTANDI (enzalutamide) for prostate cancer.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the global prostate health market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatment, drug launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the prostate health market is expected to be moderately affected over the forecast period.

Market Segmentation

By Indication
• Prostate cancer
• Benign prostatic hyperplasia (BPH)
• Prostatitis

By Treatment
• Radiation Therapy
• Surgery
• Chemotherapy
• Immunotherapy
• Hormone Therapy
• Targeted Drug Therapy

By End Users
• Hospitals
• Oncology Centers
• Ambulatory Surgical Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Pfizer Inc., Astellas Pharma Inc., Lupin Ltd, Eli Lilly and Company, Johnson & Johnson, BDR Pharmaceuticals Internationals Pvt. Ltd, Bayer AG, AstraZeneca Plc, Sanofi S.A, and Fusion Pharmaceuticals Inc. among others.

Key Developments
• In February 2023, Fusion Pharmaceuticals Inc. declared the acquisition from RadioMedix, Inc. of the investigational new drug application for an ongoing Phase 2 clinical trial evaluating 225Ac-PSMA.
• In January 2023, BDR Pharmaceuticals launched the generic Apalutamide in India to treat metastatic castration sensitive prostate cancer.

Why Purchase the Report?
• To visualize the global prostate health market segmentation based on indication, treatment, end users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global prostate health market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global prostate health market report would provide approximately 61 tables, 59 figures, and 185 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies